Lymphatic Filariasis News and Research

RSS

Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes.

People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

Washington Post examines Haiti's efforts to fight lymphatic filariasis

The Washington Post reports on Haiti's efforts to fight lymphatic filariasis, a parasitic mosquito-borne disease that can cause elephantiasis and is present in 80 percent of the country.

2 Oct 2012

Brandeis professor investigates wallpaper-like liner technology for tackling malaria

Can an innovative wallpaper-like liner help reduce the number of cases of malaria, and if so, will it be cost effective? Donald S. Shepard, a professor at the Schneider Institutes for Health Policy at the Heller School wants to know. And he has gotten the Bill and Melinda Gates Foundation to help. A grant, totaling nearly $500,000 over the next three years, will allow Shepard and collaborators to pursue their research in Kenya and Tanzania.

17 Feb 2012

Major effort to tackle neglected tropical diseases

Thirteen drug companies, the governments of the United States, Britain and the United Arab Emirates, the World Bank, the Bill and Melinda Gates Foundation, the Lions Club and other smaller charitable organizations on Monday announced a joint effort to tackle 10 neglected tropical diseases in a coordinated fashion.

31 Jan 2012

Abbott, DNDi partner to research on new treatments for NTDs

The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness.

31 Jan 2012

U.K. government to increase NTD spending fivefold between 2011 and 2015

"The U.K. government has announced a fivefold increase in spending on combating neglected tropical diseases [NTDs] as part of an international effort to help rid the world of a group of infectious diseases that currently affect one billion people and kill more than half a million every year," BMJ reports.

25 Jan 2012

International public health spending ignores neglected tropical diseases, some experts argue

The Bureau of Investigative Journalism examines what some experts are calling a serious inequity in public health spending, writing that neglected tropical diseases (NTDs) "together kill more people than maternal mortality and have a higher disease burden than malaria or tuberculosis (TB) and nearing that of HIV/AIDS. However, despite the severity of the situation, funding for NTDs is just a fraction of that spent on other diseases."

7 Sep 2011

Disease mapping could help control and eliminate loiasis, other NTDs, study says

In this End the Neglect blog post, Linda Diep, communications and grassroots assistant with the Global Network for Neglected Tropical Diseases, discusses how "mapping of Loa Loa Filariasis could help in the innovation of new strategies to eliminate and control onchocerciasis and lymphatic filariasis (LF), according to a recently released article from the open-access journal PLoS Neglected Tropical Diseases."

20 Aug 2011

Ivermectin cream demonstrates activity against head lice eggs

In a study sponsored by Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, scientists from the University of Massachusetts, Amherst presented data showing that a 0.5% ivermectin (IVM) cream formulation was active against lice eggs from permethrin resistant head lice.

11 Jul 2011

MSU professor focuses on new formulation for old drug to treat parasitic diseases

With the help of another $2 million in funding from the Bill & Melinda Gates Foundation, researchers are moving closer to setting up human clinical trials for a reformulated drug that could be the linchpin of treatment efforts against two debilitating tropical diseases.

11 Jul 2011

FDA accepts Topaz's ivermectin NDA for treatment for head lice infestations

Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for the use of ivermectin topical cream as a treatment for head lice infestations in children and adults.

7 Jun 2011

Sanofi, DNDi announce three-year research collaboration for neglected tropical diseases

The pharmaceutical company Sanofi and the Drugs for Neglected Diseases initiative (DNDi) on Monday announced a three-year research collaboration to develop drugs for nine neglected tropical diseases, RTTNews reports.

2 Jun 2011

NIAID team completes analysis of most proteins produced by elephantiasis parasite worm

A team led by Thomas B. Nutman, M.D., of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has completed a large-scale analysis of most of the proteins produced by Brugia malayi, one kind of parasitic worm that causes lymphatic filariasis, or elephantiasis.

24 May 2011

Anacor Pharma, MMV enter agreement to develop AN3661 for malaria treatment

Anacor Pharmaceuticals announced today that it has entered into a development agreement with Medicines for Malaria Venture to develop Anacor's compound AN3661 for the treatment of malaria.

18 Mar 2011

ITMNs can reduce Japanese Encephalitis transmission to humans

A new study revealed that using treated mosquito nets could drastically reduce the transmission of Japanese Encephalitis to humans.

9 Mar 2011

Anacor and iOWH establish research agreement to identify new drugs for shigellosis

Anacor Pharmaceuticals (NASDAQ:ANAC) and the Institute for OneWorld Health (iOWH) today announced the establishment of a joint research agreement to discover antibacterial compounds for treating shigellosis.

8 Mar 2011

New study on mosquito genome sequences to identify 'transposable elements'

A team of scientists at the University of California, Riverside has begun working on a mosquito research project that, if successful, will provide valuable genetic resources capable of transforming the way mosquito research is conducted around the world.

14 Feb 2011

Bill Gates' annual letter calls for focus on eradicating polio, governments to sustain foreign aid

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, "urged developed nations to help him wipe out polio 'once and for all' at an event to release his third annual letter [.pdf] Monday," Agence France-Presse reports.

2 Feb 2011

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.

1 Dec 2010

Eisai signs statement of intent with WHO to supply medicine for treatment of lymphatic filariasis

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that it has signed a statement of intent with the World Health Organization to supply free of charge a primary medicine for the treatment of lymphatic filariasis.

19 Nov 2010

Report documents increase in R&D projects on developing world diseases

Drugmakers are now working on over 100 R&D projects designed to tackle diseases of the developing world and almost 80% of them are being carried out with non-industry partners, according to a report released on Wednesday by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

15 Nov 2010